Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-114466
Abstract: BACKGROUND: TET2 (Ten-eleven-translocation-2) mutations found in 10-30% of MDS and AML patients are actionable for Azacitidine (AZA) treatment (PMID: 21828143). Although response rate of AZA in older AML patients is ~47%, rate of relapse is… read more here.
Keywords: cellworks research; research india; aza resistant; aza ... See more keywords
MCL1 Promotes Fatty Acid β-Oxidation in Therapy-Resistant AML through Cytoplasmic Sequestration of the Transcriptional Repressor IRF2BP2
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-206516
Abstract: Despite extensive efforts aimed toward the development of improved molecular therapies targeting acute myeloid leukemia (AML), clinical outcomes remain poor. Notably, targeting BCL2 with venetoclax (Ven) in combination with azacitidine (Aza) has clinically delivered significant… read more here.
Keywords: irf2bp2; mcl1; ven aza; aza resistant ... See more keywords